Venclexta™

Venclexta (US), Venclyxto (EU), (ABT-199) is a selective small molecule Bcl-2 inhibitor being investigated for the treatment of multiple cancers.

Type of Molecule

Small Molecule

Target

Bcl-2

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Acute Myeloid Leukemia (AML) EU, US
Approved
Chronic Lymphocytic Leukemia (CLL) with 17p deletion US, EU
Approved
Chronic Lymphocytic Leukemia (CLL) - first line EU, US
Approved
Chronic Lymphocytic Leukemia (CLL)- relapsed refractory EU - Submitted, US - Approved
Approved
Myelodysplatic Syndrome (MDS) US, EU
Phase 2
Multiple Myeloma (MM) n/a
Phase 3